ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neurology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,101Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 185

$2.38M Total Retail Price of All Prescriptions

Rank: 1 out of 185

675 Patients Receiving at Least One Drug in Part D
55%Patients 65 Years and Older
43% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Virginia
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 675 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

11% of this provider’s 675 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

5% of this provider’s 4,058 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$261 was the average price of a prescription from this provider, compared to $241 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 8.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Virginia
CARBIDOPA-LEVODOPA 580 510 1 2
GABAPENTIN 439 222 2 1
HYDROCODONE-ACETAMINOPHEN 391 144 S3 3 8
BACLOFEN 367 122 4 10
TOPIRAMATE 273 86 5 6
PRIMIDONE 247 117 6 9
AMANTADINE 229 150 7 42
DILANTIN 226 25 8 16
LAMOTRIGINE 226 85 8 7
CARBAMAZEPINE 207 96 10 18
PHENYTOIN SODIUM EXTENDED 205 92 11 13
PENTOXIFYLLINE 177 128 12 72
LEVETIRACETAM 170 41 13 3
PROPRANOLOL HCL 132 63 14 26
AVONEX 127 13 15 43
PROMETHAZINE HCL 120 38 R 16 69
CITALOPRAM HBR 117 55 17 19
DONEPEZIL HCL 116 110 18 4
TEGRETOL 116 12 10 18 86
ROPINIROLE HCL 115 96 20 17
AMITRIPTYLINE HCL 105 63 R 21 21
SUMATRIPTAN SUCCINATE 103 52 22 45
TRAZODONE HCL 101 43 23 35
DIVALPROEX SODIUM 95 12 24 27
COPAXONE 93 21 25 29
DIVALPROEX SODIUM ER 86 20 26 14
MECLIZINE HCL 81 64 27 95
CYMBALTA 80 40 28 11
DEXTROAMPHETAMINE SULFATE 73 20 S2 29 102
CYPROHEPTADINE HCL 73 35 R 29 102
BUSPIRONE HCL 67 0 31 109
CARISOPRODOL 66 18 R 32 59
TIZANIDINE HCL 66 0 32 41
NAPROXEN 65 30 34 110
CILOSTAZOL 63 54 35 112
ZONISAMIDE 60 27 36 25
PRAMIPEXOLE DIHYDROCHLORIDE 58 49 37 15
METHYLPREDNISOLONE 58 19 37 85
ASCOMP WITH CODEINE 58 22 S3 R 10 37 119
PAROXETINE HCL 57 39 40 90
OXCARBAZEPINE 56 0 41 32
DOXEPIN HCL 55 23 42 126
CYCLOBENZAPRINE HCL 55 0 R 42 44
TRAMADOL HCL 54 0 44 24
KEPPRA 53 0 45 56
DEPAKOTE 53 0 45 87
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 28, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.